# A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia

> **NCT07225712** · PHASE3 · RECRUITING · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** SEP-363856

## Key facts

- **NCT ID:** NCT07225712
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-22
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07225712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07225712, "A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07225712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*